Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David Pfister

Showing results (81-90 of 194) with videos related to

Pageof 20
Sort By:
BJU International|March 16, 2024
Cost-effectiveness analysis of different treatment modalities in BCG-unresponsive NMIBCConstantin Rieger, Jörg Schlüchtermann, Enno Storz, et al.
Urologic Oncology|April 23, 2024
HIVEC as an alternative option in non-muscle-invasive bladder cancer: Experiences from a high-volume centerLucas Kastner, Constantin Rieger, David Pfister, et al.
Urologie (Heidelberg, Germany)|September 13, 2024
[Primary retroperitoneal lymph node dissection in testicular germ cell cancer in clinical stage IIA/B-renaissance of an established treatment?]Julian Heidenreich, Ruben Gößmann, Felix Seelemeyer, et al.
Medical Microbiology and Immunology|September 8, 2011
No evidence for a role of xenotropic murine leukaemia virus-related virus and BK virus in prostate cancer of German patientsBaki Akgül, David Pfister, Ruth Knüchel, et al.
Aktuelle Urologie|July 21, 2017
[Female urethral diverticulum with calculus formation imitating stress incontinence]Leonidas Karapanos, Daniel Porres, David Pfister, et al.
Cancer|October 6, 2010
A phase 2 study of pemetrexed plus gemcitabine every 2 weeks for patients with recurrent or metastatic head and neck squamous cell cancerMatthew G Fury, Sofia Haque, Hilda Stambuk, et al.
European Urology Oncology|November 6, 2023
Evaluation of a miRNA-371a-3p Assay for Predicting Final Histopathology in Patients Undergoing Primary Nerve-sparing Retroperitoneal Lymphadenectomy for Stage IIA/B Seminoma or NonseminomaFelix Seelemeyer, David Pfister, Roberto Pappesch, et al.
Clinical Genitourinary Cancer|May 10, 2025
Very Early Relapse (< 1 year) in de novo Metastatic Seminoma is Associated With Reduced Overall SurvivalPia Paffenholz, F Seelemeyer, Ruben Gößmann, et al.
European Urology Oncology|January 18, 2024
Reply to Fumihiko Urabe, Takashi Yoshioka, and Takahiro Kimura's Letter to the Editor re: Felix Seelemeyer, David Pfister, Robert Pappesch, Sabine Merkelbach-Bruse, Pia Paffenholz and Axel Heidenreich. Evaluation of a miRNA-371a-3p Assay for Predicting Final Histopathology in Patients Undergoing Primary Nerve-sparing Retroperitoneal Lymphadenectomy for Stage IIA/B Seminoma or Nonseminoma. Eur Urol Oncol. In press. https://doi.org/10.1016/j.euo.2023.10.021Felix Seelemeyer, David Pfister, Robert Pappesch, et al.
Nuklearmedizin. Nuclear Medicine|October 19, 2017
PSA levels, PSA doubling time, Gleason score and prior therapy cannot predict measured uptake of [68Ga]PSMA-HBED-CC lesion uptake in recurrent/metastatic prostate cancerFrederik A Verburg, David Pfister, Natascha I Drude, et al.
Pageof 20

Showing results (81-90 of 194) with videos related to

Sort By:
Pageof 20
BJU International|March 16, 2024
Cost-effectiveness analysis of different treatment modalities in BCG-unresponsive NMIBCConstantin Rieger, Jörg Schlüchtermann, Enno Storz, et al.
Urologic Oncology|April 23, 2024
HIVEC as an alternative option in non-muscle-invasive bladder cancer: Experiences from a high-volume centerLucas Kastner, Constantin Rieger, David Pfister, et al.
Urologie (Heidelberg, Germany)|September 13, 2024
[Primary retroperitoneal lymph node dissection in testicular germ cell cancer in clinical stage IIA/B-renaissance of an established treatment?]Julian Heidenreich, Ruben Gößmann, Felix Seelemeyer, et al.
Medical Microbiology and Immunology|September 8, 2011
No evidence for a role of xenotropic murine leukaemia virus-related virus and BK virus in prostate cancer of German patientsBaki Akgül, David Pfister, Ruth Knüchel, et al.
Aktuelle Urologie|July 21, 2017
[Female urethral diverticulum with calculus formation imitating stress incontinence]Leonidas Karapanos, Daniel Porres, David Pfister, et al.
Cancer|October 6, 2010
A phase 2 study of pemetrexed plus gemcitabine every 2 weeks for patients with recurrent or metastatic head and neck squamous cell cancerMatthew G Fury, Sofia Haque, Hilda Stambuk, et al.
European Urology Oncology|November 6, 2023
Evaluation of a miRNA-371a-3p Assay for Predicting Final Histopathology in Patients Undergoing Primary Nerve-sparing Retroperitoneal Lymphadenectomy for Stage IIA/B Seminoma or NonseminomaFelix Seelemeyer, David Pfister, Roberto Pappesch, et al.
Clinical Genitourinary Cancer|May 10, 2025
Very Early Relapse (< 1 year) in de novo Metastatic Seminoma is Associated With Reduced Overall SurvivalPia Paffenholz, F Seelemeyer, Ruben Gößmann, et al.
European Urology Oncology|January 18, 2024
Reply to Fumihiko Urabe, Takashi Yoshioka, and Takahiro Kimura's Letter to the Editor re: Felix Seelemeyer, David Pfister, Robert Pappesch, Sabine Merkelbach-Bruse, Pia Paffenholz and Axel Heidenreich. Evaluation of a miRNA-371a-3p Assay for Predicting Final Histopathology in Patients Undergoing Primary Nerve-sparing Retroperitoneal Lymphadenectomy for Stage IIA/B Seminoma or Nonseminoma. Eur Urol Oncol. In press. https://doi.org/10.1016/j.euo.2023.10.021Felix Seelemeyer, David Pfister, Robert Pappesch, et al.
Nuklearmedizin. Nuclear Medicine|October 19, 2017
PSA levels, PSA doubling time, Gleason score and prior therapy cannot predict measured uptake of [68Ga]PSMA-HBED-CC lesion uptake in recurrent/metastatic prostate cancerFrederik A Verburg, David Pfister, Natascha I Drude, et al.
Pageof 20